Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

DISON I - Directly Integrated Suction and Optics System for the Treatment of Nephrolithiasis

NCT07712861 · tracked via the Priya Life Science India tracker
Sponsor
Ventaris Surgical Incorporated
Phase
Not applicable
Started
2026-10
Last updated
2026-08-05

Condition(s) studied

Kidney StonesUrolithiasisNephrolithiasis

Investigational drug(s) / intervention(s)

RIRS with Investigational Device

RIRS with Investigational Device: Investigational endourological device used during retrograde intrarenal surgery.

Study summary

A single-arm, multicenter, international, prospective interventional study designed to evaluate the safety and performance of an investigational device during retrograde intrarenal surgery for the treatment of renal calculi.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of calyceal and/or renal pelvis calculi 2. Age from 18 through 85 years 3. Maximum stone diameter between 0.5cm - 2.0cm as assessed by Non-Contrast CT scan (≤ 2 mm slice thickness) within 90 days prior to treatment 4. Willing and able to comply with all study requirements 5. Signs study-specific informed consent form Exclusion Criteria: 1. Diagnosis of calculus of the ureter 2. BMI ≥ 42 3. Significant renal impairment: stage 3a CKD or higher (eGFR \<59mL/min) 4. Active infection, including urinary tract infection 5. Urological anatomic/congenital abnormalities 6. Previous history of struvite stone in the same renal unit 7. Taking anticoagulants that cannot be stopped before and after procedure or known coagulopathy or platelet disorder (except aspirin below 100mg/d) 8. History of gross hematuria 9. Solitary functioning kidney 10. Known allergy to device materials 11. Any severe illness that would prevent complete study participation or confound study results 12. Serious concurrent medical conditions such as heart disease (e.g., myocardial infarction within 30 days, congestive heart failure - NYHA Class IV), pulmonary disease or uncontrolled diabetes. 13. History of open-heart surgery, or cardiac arrest \< 180 days prior to the date of informed consent 14. ASA III or higher 15. Taking systemic immune suppressants 16. Dementia or psychiatric condition that prevents the participant from completing required follow up 17. Contraindication to both general and spinal anesthesia 18. Participating in another investigational study that could affect responses to the study device 19. Unwilling to accept a transfusion should one be required 20. Pregnant or considering getting pregnant within the next 3 months 21. Undergoing bilateral ureteroscopy

Primary outcome measure(s)

  • Procedure success — Intraoperative
    Successful completion of the planned procedure without device-related technical complications.
  • Serious Adverse Device Effects (SADEs) — 30 days post-procedure
    Serious adverse device effects related to the investigational device.
  • Stone-Free Status — 30 days post-procedure
    Absence of residual stone fragments on CT imaging

Trial sites (5)

FacilityCityRegionStatus
Hospital Alemán Buenos Aires Argentina
Centre hospitalier de l'Universite de Montreal (CHUM) Montreal Canada
The Chinese University of Hong Kong Hong Kong Hong Kong
Muljibhai Patel Urological Hospital Nadiād India
Tauranga Urology Research Limited Tauranga New Zealand
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07712861 on ClinicalTrials.gov ↗ ← All trials in India